Financial institution of America is standing by its bullish outlook on Eli Lilly . The financial institution reiterated its purchase ranking on the pharmaceutical inventory. It additionally hiked its value goal to $1,286 from $950, which factors to 22% upside. Analyst Tim Anderson applauded Eli Lilly for sustaining its “first place” standing within the giant weight problems and diabetes market with its GLP-1 medicine, Zepbound and Mounjaro. LLY YTD mountain LLY YTD chart “Whereas the weight problems class is complicated, with many shifting components, we proceed to see LLY as remaining solidly within the lead that ought to proceed to drive outsized progress for a few years to come back, at a valuation that’s affordable given this context,” he wrote. He additionally highlighted the corporate’s promising medicine pipeline. Anderson believes Eli Lilly will launch its new oral remedy orforglipron in early 2026 versus earlier expectations of late 2026, which lifts his income and earnings estimates for the upcoming 12 months. “The corporate is nearing the launch of a intently watched, new, oral GLP1 (orforglipron) on an accelerated foundation (guides for March 2026) because it was awarded one of many FDA’s first Commissioner’s Nationwide Precedence Vouchers,” he stated. “On the similar time, it’s pushing via a broad section 3 growth program with its high-potency product, retatrutide (aka ‘triple G’), with first outcomes doubtless coming round year-end.” One other bullish catalyst, Anderson stated, are rising valuations throughout the large-cap biopharma sector. This, he stated, is partially as a result of market’s re-embrace of the sector because the Trump administration’s healthcare coverage priorities have develop into clearer. Shares of Eli Lilly have climbed 37% this 12 months.